Pretoria Court Blocks Appeal in Semaglutide Compounding Fight

What Happened

The High Court of South Africa, Gauteng Division, Pretoria has refused a Pretoria-based company permission to appeal an order barring it from selling compounded semaglutide — closing, for now, the company's legal avenue to keep moving unapproved copies of a blockbuster GLP-1 medicine.

The ruling is the latest round in a fight initiated by Novo Nordisk, whose registered semaglutide products are the reference medicines in the case. The interim order, granted earlier in 2026, restrained the company — iDexis (Pty) Ltd, trading as Sentra Pharmacy — from selling semaglutide-based products while the underlying dispute proceeds.

The company had argued that its compounded semaglutide was similar to registered products and therefore permissible. The court was not persuaded that an appeal held reasonable prospects of success, a standard that effectively ends the interim-stage challenge and keeps the sales ban in force.

Who Is Affected

• South African patients who obtained semaglutide through compounding channels, whose supply now faces judicial scrutiny.
• Compounders and pharmacies in markets where GLP-1 demand has outrun registered supply, and where courts are increasingly willing to interdict unapproved copies.
• Researchers and gray-market sellers, who should read the judgment as part of a global pattern: brand enforcement has expanded from counterfeiters to compounders.

Timeline

• 2023-2025 — Global GLP-1 shortages spawn a cottage industry of compounded semaglutide across multiple jurisdictions.
• June 2026 — The court grants an interim interdict preventing the company from selling compounded semaglutide, following the originator's application.
• September 2026 — The court refuses leave to appeal the interim order, keeping the restraint in force while the main case proceeds.
• Ongoing — The substantive litigation between the parties continues.

What This Means for Researchers

Jurisdiction by jurisdiction, the legal footing under compounded GLP-1s is disappearing. The US has moved to strike the three flagship molecules from bulk-compounding lists; UK authorities have moved to asset seizures; a South African court has now interdicted a domestic compounder at the request of an originator. For researchers, the enforcement trend narrows the legitimate channels for acquiring semaglutide and its analogues — and raises the reputational and legal risk of suppliers who kept selling through the crackdown. Knowing where a supplier stands legally is now part of sourcing diligence.

How to Verify Your Peptides

• The semaglutide purity testing guide explains how analytical testing confirms that what you bought matches the label claim.
• HPLC vs LC-MS compares the two workhorse methods for identity and content verification.
• Our trusted third-party lab directory lists laboratories that accept researcher submissions.

Safe Alternatives

• The semaglutide peptide profile summarizes the approved-medicine evidence base, while tirzepatide covers the dual-agonist alternative.
• Our vendor directory scores suppliers on testing transparency, shipping reliability, and regulatory posture — the criteria that matter most in a tightening enforcement climate.

Sources

• Court records and regulatory announcements
• Industry reports